REPL
Replimune Group, Inc.
Set alert
17.61 USD +0.22 +1.27%
16.64 Day range 18.27
1.70 52-week range 17.61
- YTD
- +81.17%
- 1 year
- +71.80%
- Open
- 17.49
- Prev close
- 17.39
- Mkt cap
- 1.67B
- Vol
- 3.85M
- Avg vol
- 3.47M
- EPS
- -2.79
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 16.64
- High
- 18.27
- Forward P/E
- -27.19
- Beta
- 0.00
- Short ratio
- 11.50
- Inst. own
- 105.29%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 2, 2027
- 50-d avg
- 13.51
- 200-d avg
- 9.24
- 1y target
- 23.33
Key statistics
- Market cap
- 1.67B
- Enterprise value
- 1.47B
- Trailing P/E
- 0.00
- Forward P/E
- -27.19
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 8.15
- EPS (TTM)
- -2.79
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -149.46M
- Total cash
- 307.83M
- Total debt
- 127.19M
- Return on equity
- -115.80%
- Shares outstanding
- 94.80M
- Short % of float
- 34.00%
- 50-day average
- 13.51
- 200-day average
- 9.24
Analyst view
Consensus: buy
Buy
Price target (mean) 23.33 +32.5% upside
Now 17.61
- Target (low)
- 14.00
- Target (mean)
- 23.33
- Target (high)
- 31.00
Ratings (0m) 8 7 buy · 0 hold · 1 sell
- Strong buy2
- Buy5
- Hold0
- Sell1
- Strong sell0
Next earnings
Feb 2, 2027
Expected Feb 2, 2027. Consensus EPS estimate -0.47.
Financials — quick view
REPL Revenue — quarterly 0
REPL Net income — quarterly -57.12M
REPL EPS — quarterly -0.54
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 2, 2027 | Dec 30, 2026 | -0.58357 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | -0.784 | -0.54 | +0.24 | +31.12% |
| Aug 14, 2026 | Jun 30, 2026 | -0.694 | -0.72 | -0.03 | -3.75% |
| Jun 29, 2026 | Mar 31, 2026 | -0.73 | -0.76 | -0.03 | -4.11% |
| Feb 3, 2026 | Dec 31, 2025 | -0.7683 | -0.77 | 0.00 | -0.22% |
| Nov 6, 2025 | Sep 30, 2025 | -0.87 | -0.90 | -0.03 | -3.45% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | Leerink Partners | main | Outperform | Outperform |
| Aug 26, 2026 | JP Morgan | main | Overweight | Overweight |
| Aug 7, 2026 | JP Morgan | main | Overweight | Overweight |
| Aug 7, 2026 | Wedbush | up | Neutral | Outperform |
| Aug 4, 2026 | Leerink Partners | up | Market Perform | Outperform |
| Jul 31, 2026 | Wedbush | main | Neutral | Neutral |
About Replimune Group, Inc.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- replimune.com
News
- Leerink Partners Maintains Outperform on Replimune Group, Raises Price Target to $31
- Replimune: 3 Key Takeaways for Long-Term Investors
- Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript
- Replimune Group Q2 2027 Earnings Call Transcript
- Replimune Group Q2 EPS $(0.54) Beats $(0.77) Estimate
- Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
- Replimune Group Announces Commercial Availability Of TUDRIQEV In U.S. To Treat Unresectable Advanced Cutaneous Melanoma
- JP Morgan Maintains Overweight on Replimune Group, Raises Price Target to $21
- Replimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate
- Replimune Prices ~$150M Underwritten Offering Of 9,701,490 Shares And Warrants At $12.06 Per Unit
Your note
Sign in to keep a note on REPL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ASTLEY-SPARKE PHILIP | Director | Stock Gift | Aug 19, 2026 | 1,362,410 |
| DHINGRA KAPIL | Director | Sale | Dec 8, 2025 | 0 |
| HILL EMILY LUISA | Chief Financial Officer | Sale | Aug 16, 2026 | 215,852 |
| PATEL SUSHIL | Chief Executive Officer | Sale | Aug 9, 2026 | 708,151 |
| SARCHI CHRISTOPHER | Officer | Sale | May 31, 2026 | 180,962 |
| SCHWENDENMAN ANDREW | Officer | Sale | Aug 9, 2026 | 99,425 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 11.65% | 11,045,336 | 194.51M | Jun 29, 2026 |
| Blackrock Inc. | 9.45% | 8,958,535 | 157.76M | Jun 29, 2026 |
| RTW Investments LP | 7.82% | 7,411,581 | 130.52M | Jun 29, 2026 |
| Ridgeback Capital Investments L.P. | 7.71% | 7,310,656 | 128.74M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 4.79% | 4,541,018 | 79.97M | Jun 29, 2026 |
| State Street Corporation | 4.68% | 4,440,144 | 78.19M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.62% | 2,487,958 | 43.81M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.20% | 2,083,494 | 36.69M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.08% | 1,972,684 | 34.74M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.91% | 865,966 | 15.25M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.90% | 854,089 | 15.04M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 Value ETF | 0.80% | 761,659 | 13.41M | Sep 29, 2026 |